EBViously, a spin-off of Helmholtz Munich, officially started operations on 11 November 2024. The company is developing a preventive vaccine against diseases caused by the Epstein-Barr virus (EBV)
The development of an effective vaccine against the hepatitis C virus has been an enormous challenge for decades due to the high genetic diversity of the virus. The research team led by DZIF scientist
Two DZIF junior scientists—Prof Philipp Schommers and Dr Alexander Simonis—have been honoured with silver medals by the Walter Siegenthaler Society for their fundamental medical research in the field
